Attached files
| file | filename |
|---|---|
| EX-3.2 - EXHIBIT 3.2 - Eloxx Pharmaceuticals, Inc. | tv481837_ex3-2.htm |
| EX-99.5 - EXHIBIT 99.5 - Eloxx Pharmaceuticals, Inc. | tv481837_ex99-5.htm |
| EX-99.4 - EXHIBIT 99.4 - Eloxx Pharmaceuticals, Inc. | tv481837_ex99-4.htm |
| EX-99.3 - EXHIBIT 99.3 - Eloxx Pharmaceuticals, Inc. | tv481837_ex99-3.htm |
| EX-99.2 - EXHIBIT 99.2 - Eloxx Pharmaceuticals, Inc. | tv481837_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Eloxx Pharmaceuticals, Inc. | tv481837_ex99-1.htm |
| EX-23.1 - EXHIBIT 23.1 - Eloxx Pharmaceuticals, Inc. | tv481837_ex23-1.htm |
| EX-10.4 - EXHIBIT 10.4 - Eloxx Pharmaceuticals, Inc. | tv481837_ex10-4.htm |
| EX-10.3 - EXHIBIT 10.3 - Eloxx Pharmaceuticals, Inc. | tv481837_ex10-3.htm |
| EX-10.2 - EXHIBIT 10.2 - Eloxx Pharmaceuticals, Inc. | tv481837_ex10-2.htm |
| EX-10.1 - EXHIBIT 10.1 - Eloxx Pharmaceuticals, Inc. | tv481837_ex10-1.htm |
| EX-3.1 - EXHIBIT 3.1 - Eloxx Pharmaceuticals, Inc. | tv481837_ex3-1.htm |
| 8-K - 8-K - Eloxx Pharmaceuticals, Inc. | tv481837_8k.htm |
Exhibit 16.1
December 22, 2017
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Sevion Therapeutics, Inc.’s statements included under Item 4.01 of Form 8-K filed on December 22, 2017 by Eloxx Pharmaceuticals, Inc. and we agree with such statements concerning our firm.
/s/ RSM US LLP